1144 related articles for article (PubMed ID: 18729068)
21. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease.
Andoh A; Deguchi Y; Inatomi O; Yagi Y; Bamba S; Tsujikawa T; Fujiyama Y
Oncol Rep; 2006 Jul; 16(1):103-7. PubMed ID: 16786130
[TBL] [Abstract][Full Text] [Related]
22. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis.
Foell D; Hernández-Rodríguez J; Sánchez M; Vogl T; Cid MC; Roth J
J Pathol; 2004 Nov; 204(3):311-6. PubMed ID: 15476267
[TBL] [Abstract][Full Text] [Related]
23. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
Stadnicki A; Mazurek U; Plewka D; Wilczok T
Int Immunopharmacol; 2003 Jul; 3(7):939-44. PubMed ID: 12810351
[TBL] [Abstract][Full Text] [Related]
24. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
Shkoda A; Werner T; Daniel H; Gunckel M; Rogler G; Haller D
J Proteome Res; 2007 Mar; 6(3):1114-25. PubMed ID: 17330946
[TBL] [Abstract][Full Text] [Related]
25. Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: a comparative study of inflammatory bowel disease and colonic neoplasms.
Vainer B; Horn T; Nielsen OH
Scand J Gastroenterol; 2006 Mar; 41(3):318-25. PubMed ID: 16497620
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
[TBL] [Abstract][Full Text] [Related]
27. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease.
Kruidenier L; Kuiper I; van Duijn W; Marklund SL; van Hogezand RA; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):7-16. PubMed ID: 12950012
[TBL] [Abstract][Full Text] [Related]
28. Gastrin releasing peptide receptor expression is decreased in patients with Crohn's disease but not in ulcerative colitis.
ter Beek WP; Muller ES; Van Hogezand RA; Biemond I; Lamers CB
J Clin Pathol; 2004 Oct; 57(10):1047-51. PubMed ID: 15452158
[TBL] [Abstract][Full Text] [Related]
29. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype.
Meijer MJ; Mieremet-Ooms MA; van der Zon AM; van Duijn W; van Hogezand RA; Sier CF; Hommes DW; Lamers CB; Verspaget HW
Dig Liver Dis; 2007 Aug; 39(8):733-9. PubMed ID: 17602907
[TBL] [Abstract][Full Text] [Related]
30. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.
Agius LM
J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386
[TBL] [Abstract][Full Text] [Related]
31. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease.
van de Logt F; Day AS
J Dig Dis; 2013 Feb; 14(2):62-7. PubMed ID: 23146044
[TBL] [Abstract][Full Text] [Related]
32. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
[TBL] [Abstract][Full Text] [Related]
33. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease.
Palatka K; Serfozo Z; Veréb Z; Hargitay Z; Lontay B; Erdodi F; Bánfalvi G; Nemes Z; Udvardy M; Altorjay I
Scand J Gastroenterol; 2005 Jun; 40(6):670-80. PubMed ID: 16036527
[TBL] [Abstract][Full Text] [Related]
34. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease.
Vetrano S; Rescigno M; Cera MR; Correale C; Rumio C; Doni A; Fantini M; Sturm A; Borroni E; Repici A; Locati M; Malesci A; Dejana E; Danese S
Gastroenterology; 2008 Jul; 135(1):173-84. PubMed ID: 18514073
[TBL] [Abstract][Full Text] [Related]
35. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.
Sugi K; Saitoh O; Hirata I; Katsu K
Am J Gastroenterol; 1996 May; 91(5):927-34. PubMed ID: 8633583
[TBL] [Abstract][Full Text] [Related]
36. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation.
Mazzucchelli L; Hauser C; Zgraggen K; Wagner H; Hess M; Laissue JA; Mueller C
Am J Pathol; 1994 May; 144(5):997-1007. PubMed ID: 8178948
[TBL] [Abstract][Full Text] [Related]
37. Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease.
Bischoff SC; Mayer J; Nguyen QT; Stolte M; Manns MP
Am J Gastroenterol; 1999 Dec; 94(12):3521-9. PubMed ID: 10606314
[TBL] [Abstract][Full Text] [Related]
38. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease.
Danese S; Sgambato A; Papa A; Scaldaferri F; Pola R; Sans M; Lovecchio M; Gasbarrini G; Cittadini A; Gasbarrini A
Am J Gastroenterol; 2005 Apr; 100(4):886-95. PubMed ID: 15784037
[TBL] [Abstract][Full Text] [Related]
39. Relationship between fecal lactoferrin and inflammatory bowel disease.
Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
[TBL] [Abstract][Full Text] [Related]
40. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
Saniabadi AR; Hanai H; Suzuki Y; Ohmori T; Sawada K; Yoshimura N; Saito Y; Takeda Y; Umemura K; Kondo K; Ikeda Y; Fukunaga K; Nakashima M; Beretta A; Bjarnason I; Lofberg R
J Clin Apher; 2005 Oct; 20(3):171-84. PubMed ID: 15892107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
